Morgan Stanley Fate Therapeutics Inc Transaction History

Morgan Stanley

$1.36 Trillion
Q1 2025

A detailed history of Morgan Stanley transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Morgan Stanley holds 2,240,058 shares of FATE stock, worth $3 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,240,058

Previous 2,822,183 20.63%

Holding current value

$3 Million

Previous $4.66 Million 62.01%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$0.79 - $1.87 $459,878 - $1.09 Million	-582,125 Reduced 20.63%	2,240,058 $1.77 Million
Q4 2024 Feb 14, 2025	SELL	$1.61 - $3.35 $388,393 - $808,147	-241,238 Reduced 7.87%	2,822,183 $4.66 Million
Q3 2024 May 14, 2025	SELL	$3.12 - $5.57 $263,852 - $471,043	-84,568 Reduced 2.69%	3,063,421 $10.7 Million
Q3 2024 Nov 14, 2024	SELL	$3.12 - $5.57 $263,852 - $471,043	-84,568 Reduced 2.69%	3,063,421 $10.7 Million
Q2 2024 May 14, 2025	BUY	$3.26 - $7.08 $1.06 Million - $2.31 Million	325,806 Added 11.54%	3,147,989 $10.3 Million
Q2 2024 Oct 17, 2024	BUY	$3.26 - $7.08 $267,972 - $581,976	82,200 Added 2.68%	3,147,989 $10.3 Million
Q2 2024 Aug 14, 2024	BUY	$3.26 - $7.08 $267,972 - $581,976	82,200 Added 2.68%	3,147,989 $10.3 Million
Q1 2024 Oct 17, 2024	SELL	$3.54 - $8.35 $290,988 - $686,370	-82,200 Reduced 2.61%	3,065,789 $22.5 Million
Q1 2024 Aug 16, 2024	BUY	$3.54 - $8.35 $6.18 Million - $14.6 Million	1,744,433 Added 132.02%	3,065,789 $22.5 Million
Q1 2024 May 15, 2024	BUY	$3.54 - $8.35 $6.18 Million - $14.6 Million	1,744,433 Added 132.02%	3,065,789 $22.5 Million
Q4 2023 Aug 16, 2024	SELL	$1.65 - $3.94 $3.01 Million - $7.2 Million	-1,826,633 Reduced 58.03%	1,321,356 $4.94 Million
Q4 2023 Feb 13, 2024	SELL	$1.65 - $3.94 $178,299 - $425,756	-108,060 Reduced 7.56%	1,321,356 $4.94 Million
Q3 2023 Nov 15, 2023	BUY	$2.02 - $5.04 $308,219 - $769,023	152,584 Added 11.95%	1,429,416 $3.03 Million
Q2 2023 Aug 14, 2023	BUY	$4.76 - $6.59 $69,767 - $96,589	14,657 Added 1.16%	1,276,832 $6.08 Million
Q1 2023 May 15, 2023	SELL	$4.24 - $11.12 $2.02 Million - $5.29 Million	-475,900 Reduced 27.38%	1,262,175 $7.19 Million
Q4 2022 Feb 14, 2023	BUY	$9.86 - $23.83 $3.63 Million - $8.78 Million	368,354 Added 26.89%	1,738,075 $17.5 Million
Q3 2022 Nov 14, 2022	SELL	$21.04 - $36.06 $5.36 Million - $9.18 Million	-254,548 Reduced 15.67%	1,369,721 $30.7 Million
Q2 2022 Oct 27, 2022	BUY	$17.78 - $42.39 $6.98 Million - $16.6 Million	392,467 Added 31.86%	1,624,269 $40.3 Million
Q2 2022 Aug 15, 2022	BUY	$17.78 - $42.39 $6.98 Million - $16.6 Million	392,467 Added 31.86%	1,624,269 $40.3 Million
Q1 2022 Oct 27, 2022	SELL	$29.67 - $60.28 $11.6 Million - $23.7 Million	-392,467 Reduced 24.16%	1,231,802 $47.8 Million
Q1 2022 May 13, 2022	SELL	$29.67 - $60.28 $11.8 Million - $24.1 Million	-399,274 Reduced 24.48%	1,231,802 $47.8 Million
Q4 2021 Feb 14, 2022	BUY	$47.84 - $64.34 $27.3 Million - $36.7 Million	570,835 Added 53.84%	1,631,076 $95.4 Million
Q3 2021 Nov 15, 2021	BUY	$59.27 - $95.73 $62.8 Million - $101 Million	1,060,241 New	1,060,241 $62.8 Million

Others Institutions Holding FATE

# of Institutions

144

Shares Held

97M

Call Options Held

56.7K

Put Options Held

5.4K

View Full List

About FATE THERAPEUTICS INC

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $130M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

More about FATE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account